Lentivirus Strategy and How It Affects Infection of CD4 T Cells and Myeloid Cells
Official title: Lentivirus Replication Strategy and Pathogenesis
Funded at Emory University · NIH-11620200 · Data updated 2026-11-12
This NIH grant supports research to understand how lentiviruses infect CD4 T cells and certain immune cells, and how viral tricks help them multiply, with potential implications for treating coronavirus-related concerns.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | January 19, 2018 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $163,549 |
| NIH project number | 3R01AI136581-09S1 |
| Project ID | NIH-11620200 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable to patient recruitment in this project as described (laboratory and cell-based studies).
✕Less likely to help
No direct patient participation is described in this grant as presented.
What this research studies
This project aims to uncover the detailed steps that lentiviruses use to infect different immune cells, including how they cope with cellular barriers in nondividing cells. Researchers will study genetic features of the virus, such as the central PPT, and how these elements influence viral DNA synthesis in cells with limited resources. The work combines molecular biology and virology to map the mechanisms that enable rapid viral evolution and escape from host defenses. Findings could inform future therapies or vaccines that limit viral replication in humans. The study uses human-derived cell models to explore these pathways in the context of disease-relevant cell types.
Why it matters
Potential benefit: Better understanding of how lentiviruses replicate in human immune cells could guide development of therapies or preventive strategies against viral infections.
How similar studies have gone: Previous work shows that HIV-1 and related lentiviruses use PPT/cPPT dynamics to manage DNA synthesis under restrictive conditions, suggesting this area is scientifically promising.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Kim, Baek — Emory University
- Study coordinator: Kim, Baek
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.